Background
Highly Active Antiretroviral Therapy (HAART) has revolutionized the treatment of HIV-1 disease and is primarily responsible for substantial improvements in the survival of HIV-1-infected patients seen in the last decade. However, the search for development of novel antiretroviral agents is ongoing and is largely driven by issues relating to drug resistance, formulation of drug combinations, pharmacokinetic profiles and toxicity. For example, combinations of nucleoside reverse transcriptase inhibitors (NRTIs) widely used in adult disease and for the prevention of maternal-fetal HIV-1 transmission have been instrumental in prolonging the lives of adults and saving the lives of thousands of children [
1‐
4]. However, concern regarding mitochondrial and other toxicities in adults [
5,
6] and in HIV-1-uninfected children exposed
in utero [
7‐
9] to antiretroviral drugs has underscored the importance of designing strategies to both complement current antiretroviral cocktails and attenuate their toxic properties.
Amifostine [H
2N(CH
2)
3NH(CH
2)
2S(PO
3H
2)], the FDA-approved drug Ethyol
http://www.ethyol.com/ is an organic thiophosphate that is dephosphorylated
in vivo to the reduced free thiol WR1065 [H
2N-(CH
2)
3NH-(CH
2)
2SH]. Amifostine inhibits radiation-induced mutagenesis in human [
10] and hamster [
11] cell lines. WR1065 selectively protects normal tissues, but not tumors, against ionizing radiation damage and chemotherapeutic drug cytotoxicity [
12‐
14]. This compound has multiple biological activities, including ability to: detoxify reactive metabolites of chemotherapeutic agents; scavenge free radicals; modulate apoptosis; alter gene expression; and up-regulate mitochondrial manganese-superoxide dismutase [
12,
15].
Other thiols [
16‐
18], and an analog of WR1065 [
19], were reported to have antiretroviral activity. In addition, we showed in a pilot study that WR1065, the active free thiol metabolite, inhibits HIV-1 replication [
20]. The cell culture studies presented here, using HIV-1 and the Simian Immunodeficiency Virus (SIV), are important preliminary steps towards our ultimate goal of evaluating the clinical efficacy of amifostine as an antiretroviral, or adjuvant-antiretroviral and/or adjuvant agent.
In vitro studies are limited to the use of WR1065 because cells typically lack the alkaline phosphatase that is required to activate amifostine. Here we present: 1) the dose-response relationship for WR1065 antiretroviral activity in HIV-1-infected human T-cell blasts (TCBs) in the absence and presence of AZT; and 2) the antiretroviral effects of WR1065 in cultured TCBs from macaques infected chronically (14 months) with SIV.
Methods
Drug exposure and evaluation of virus replication in human T-cell blasts (TCBs)
Fresh human peripheral blood mononuclear cells (PBMC, from the NIH Transfusion Center) were cultured in 250 ml flasks (2 × 106 cells/ml) for 48 hr in RPMI-1640 media (ATCC, Manassas, VA) containing 10% fetal bovine serum (Hyclone, Logan, UT), 1% penicillin/streptomycin/glutamine (Invitrogen, Gaithersburg, MD), 10 U/ml interleukin 2 (IL2, BD Biosciences, San Jose, CA) and 20 μg/ml phytohemagglutinin (PHA, Sigma, St. Louis, MO). After 48 hr, the cells were washed to remove PHA and the resulting PHA-stimulated T-cell blasts (human TCBs) were transferred to 96 well microtiter plates (0.5 × 106 cells/well), infected with HIV-1BZ-167(gift from S. Sharpe, New York University, New York, NY) at 170-200 50% tissue culture infectious dose/105 target cells for 2 hr, and subsequently incubated with 2.5-103.0 μM WR1065 (Chemical Carcinogen Reference Standard Repository, Kansas City, MO) and/or 0.002-0.117 μM AZT (Sigma-Aldrich Inc., St. Louis, MO) for 72 hr. Cells were then harvested and evaluated for HIV-1 replication by RETRO-TEK HIV-1 p24 Extended Range Elisa Kit (ZeptoMetrix, Buffalo, NY) or by HIV-1 p24 Antigen Capture Assay Kit (Biological Products Laboratory, FCRDC, Frederick, MD).
To compare the metabolite WR1065 with the parent compound amifostine, in one experiment 50.0 μM amifostine (Chemical Carcinogen Reference Standard Repository) was added. Due to the lack of alkaline phosphatase in cultured human cells, we pre-incubated the amifostine with alkaline phosphatase (Sigma-Aldrich Inc.), at 1 U per 100 μl of media containing 50 μM amifostine, to generate WR1065. In experiments designed to examine virus replication with the combination of AZT and WR1065, the standard curve for AZT included concentrations between 0 and 23.0 ηM and WR1065 was used at either 18.7 or 26.0 μM.
Cell survival of human TCBs
Drug-induced cell viability at 72 hr was determined by Trypan blue exclusion [
20,
21] in human TCBs grown in a second 96-well microtiter plate, where cells were exposed to drugs in the absence of HIV-1 inoculation. Cells from triplicate wells were mixed with Trypan blue and counted twice by hemocytometer. Numbers of viable (unstained) cells were expressed as a percentage of total (stained plus unstained) cells.
To examine apoptosis as a measure of cell viability in human TCBs infected with HIV-1 and treated with drug, we assayed for Annexin V (as previously described [
22]). Cells taken from the wells used for p24 protein analysis were subjected to flow cytometry for this analysis and sorted on the basis of Annexin V positivity (apoptotic) and negativity (non-apoptotic).
Flow Cytometry for determination of cell cycle parameters in human TCBs cultured in the presence of WR1065
Flow cytometry was used to evaluate the integrity of cell cycle parameters in human TCBs exposed to 0, 9.5 and 18.7 μM WR1065 according to the protocol described above. Harvested cells were pelleted and washed with culture media without serum before they were fixed overnight in 1 ml of ice-cold 70% ethanol, pelleted by centrifugation and incubated with Ribonuclease A (Sigma-Aldrich Inc.) at room temperature for 20 min. Propidium iodide (20-50 μg/ml) (Molecular Probes, Eugene, OR) was added to each cell suspension and cells were kept in the dark at 4°C overnight. Cells were passed through a fluorescence activated flow cytometer (FACSCalibur, BD Biosciences, San Jose, CA) using the doublet discrimination module, and data were acquired using CellQuest (BD Biosciences) software. Cell cycle analysis was performed using ModFit software (Venty Software, Topsham, ME). Percentages of cells in G0-G1, S and G2-M phases were calculated directly by the software.
Culture of SIV-infected macaque TCBs and exposure to WR1065
Blood used to prepare macaque PBMC was collected from Macaca mulatta monkeys (macaques) numbered M612, M642 and M674. The macaques, housed at Advanced BioScience Laboratories (ABL), Inc. (Rockville, MD), had been infected with SIVMac251 for 14 months before these experiments were performed. The animals were maintained and treated under conditions approved by the Association for Assessment and Accreditation of Laboratory Animal Care, and all procedures were performed in accordance with humane principles for laboratory animal care. Protocols were reviewed and approved by the Institutional Animal Care and Use Committee of ABL, Inc.
Macaque PBMC (106 cells/ml), prepared from blood using Ficoll gradient centrifugation, were depleted of CD8+ cells by magnetic bead separation using the CD8 Microbead Kit for non-human primates (Miltenyi, Auburn, CA). Briefly, whole PBMC were incubated with microbeads conjugated to an anti-CD8+ antibody and then washed. Cells were resuspended in Dulbecco's phosphate buffered saline (DPBS, Invitrogen, Carlsbad, CA) supplemented with 5% bovine serum albumin (BSA) and 2 mM EDTA, and run through a magnetic column. The flow-through material contained PBMC depleted (>99%) of CD8+ T-cells, which were then counted and cultured using the same media as for the human TCBs (above). Once in culture, PBMC were incubated for 48 hr in the presence of PHA to activate remaining T-cells, as described above for human TCBs. These cells, macaque CD8+ T cell-depleted, PHA-stimulated macaque T-cell blasts (TCBs) were transferred to 48-well plates (500 μL media/well, 0.5 × 106 cells/well, 6 wells/macaque) and cultured for an additional 17 days in the presence of 0, 9.5 or 18.7 μM WR1065. The medium was changed twice weekly for a total of 4 times, and fresh WR1065 was added at each medium change. Cell survival was evaluated on days 10 and 17 using the Cell Titer 96® Aqueous Non-Radioactive Cell Proliferation (MTS) Assay (Promega Corp., Madison, WI). SIV levels were assayed using the p27 Antigen Assay kit (Beckman Coulter, Fullerton, CA) on days 3, 7, 10, 14 and 17.
Discussion
These experiments demonstrate that WR1065 is effective in significantly reducing HIV-1 replication in cultured human TCBs infected with HIV-1 for 2 hr prior to treatment, and in macaque TCBs cultured from SIV-infected macaques for 17 days with the addition of WR1065. Taken together, these studies show inhibition of replication of two distinct retroviruses in TCBs from two different primate species. The data suggest that the parent drug, amifostine, which is non-toxic when used at very high doses in vivo, may have clinical utility. In addition, in combination studies using both AZT and WR1065 in human TCBs, we found that addition of WR1065 to a non-saturating dose of AZT resulted in more effective inhibition of HIV-1 replication than was observed with AZT alone, suggesting that amifostine might also be useful as supplementary or adjuvant therapy.
In a previous manuscript [
20] we reported three pilot experiments using HIV-1, AZT and WR1065. The WR1065 doses used for those studies were very high (up to 1000 μM), and in only one of the three experiments did the dose range extend below 100 μM WR1065. Therefore, more information was required to determine the feasibility of initiating studies in primates. The experiments presented in this manuscript are essential because they define the dose-response parameters and show consistency in HIV-1 inhibition for >20 experiments. In addition, in this study the cytotoxicity was carefully defined in cell cycle and other experiments that were not performed previously. Finally, if amifostine is to be evaluated for use in humans it is important to show evidence of antiviral efficacy in SIV-infected macaques, and the
in vitro studies presented here are a necessary a first step in the process.
Whereas amifostine has little or no toxicity in the clinic, WR1065 was cytotoxic in our cell cultures. This may have occurred partially as a result of the formation of WR1065 disulfide metabolites and other compounds. In long-term experiments this cytotoxicity can be prevented by the addition of aminoguanidine to the culture media [
23]. However, because of the short duration of our human TCB studies we chose not to use aminoguanidine, and we lowered the WR1065 dose to ≤ 26 μM to obtain acceptable cell survival. Whereas the role of aminothiol oxidative metabolites may be critical for the interpretation of the cell culture studies, toxic metabolites do not appear to be an issue
in vivo when amifostine is given. Additional experiments will be required to determine the
in vivo efficacy of this drug.
The experiments in which AZT and WR1065 were given together were designed to investigate whether the antiviral efficacy of AZT might be inhibited in the presence of WR1065. The four experiments presented in Table
3 all showed that AZT was active in the presence of WR1065. In addition they suggested that there might be synergism in antiretroviral capacity when the drugs were combined, because for the informative doses, the AZT % Inhibition of HIV-1 replication was increased when WR1065 was added. This is an intriguing pilot finding, which requires much more detailed experimentation and statistical analysis for confirmation.
Amifostine, when dephosphorylated to WR1065, has cytoprotective activity that appears to be related both to the free thiol group and to the disulfide formed by interaction of the two WR1065 free thiol groups [
13]. These aminothiol metabolites compete with polyamines to alter gene expression, stabilize DNA by electrostatic intercalation [
12], act as free radical scavengers by binding to NFκB and p53 [
24,
25], thereby increasing transactivation of downstream genes, including manganese superoxide dismutase (MnSOD)[
15]. WR1065 inhibits the catalytic site of Topoisomerase II [
15] and up-regulates p21 [
26,
27]. Both of these genes are involved in cell cycle arrest and are relevant to the finding that WR1065-induced cytoprotection requires an intact and functioning DNA repair mechanism [
12].
Amifostine is used at high doses to protect against the lethality of radiotherapy and chemotherapy in adults [
28], and in pediatric oncology [
29‐
31]. The recommended daily amifostine dose is 910 mg/M
2, but higher doses are tolerated, and up to 2700 mg/M
2 has been used in children [
32‐
34]. Pharmacokinetic studies, performed in humans and in monkeys [
30,
33,
34], showed that administration of amifostine is followed by rapid dephosphorylation to WR1065, slower elimination of WR1065, and formation of various longer-lived metabolites. In one pharmacokinetic study, in children given 825 mg amifostine/M
2, the peak concentration of WR1065 in whole blood, plasma and blood cells was 75, 85 and 83 μM, respectively [
30]. In cynomolgus monkeys given subcutaneous amifostine at 260 mg/M
2, the WR1065 peak plasma concentration was 104 μM [
33]. In addition, bioavailability after oral administration yielded metabolites that persisted in the plasma for several hours [
34]. The ability to achieve plasma and
in vivo intracellular WR1065 levels in the range of 100 μM suggests that it may be possible to dose HIV-1 infected patients with amifostine levels that will sustain antiretroviral activity using FDA-recommended doses of drug. If amifostine is shown to be an effective clinical antiretroviral agent, it may be useful in patients who have developed resistance to conventional antiretroviral therapy, or as prophylaxis in HIV-1-uninfected health care workers who have been occupationally-exposed to HIV-1.
The mechanism(s) that may contribute to the antiretroviral efficacy of these drugs are still largely a matter of conjecture. One possible explanation comes from the importance of thiol-disulfide exchange in fusion of the HIV-1 envelope with host cell membrane, a process facilitated by protein disulfide isomerase [
35,
36]. Inhibitors of this enzyme prevent the establishment of virus infection. Also, retroviral inactivation has been accomplished using oxidizing agents that react with cysteine thiols in the zinc finger motifs of the retroviral nucleocapsid proteins [
37,
38]. The organic thiophosphate WR-151327, a methylated derivative of amifostine, inhibited HIV-1 reverse transcriptase activity and prevented the production of viral protein synthesis in a promonocytic cell line chronically-infected with HIV-1[
19]. Inhibition of viral replication was maximal at 15 mM, a dose which exhibited no cytotoxicity for up to 7 days in culture. Several mechanisms, including modulation of glutathione, and NFκB-dependent and -independent pathways, were speculated to contribute to the observed inhibition of virus replication, and it is possible that those mechanisms may be relevant to our experiments with WR1065[
19].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DMW and VEW had the original idea for the use of WR1065 to attenuate the toxicity of nucleoside reverse transcriptase inhibitors, and from the beginning this was a collaboration with GMS who contributed labs with P3 containment where HIV-1 could be used. DMW and VEW provided essential information regarding the stability of WR1065 in culture, and funding to share the cost of the amifostine synthesis. MCP wrote the protocols, calculated the data, prepared the graphs and tables and wrote the paper. The actual experiments were performed in the laboratories of MCP and GMS using systems developed by GMS. GMS also provided critical conceptual input. OAO, JB, and AWH grew and treated the cells and performed the cytotoxicity assays and immunoassays for virus titer. OAO provided important conceptual input regarding the cytotoxicity assays. GF provided the monkey cells and was involved in the conceptual design of the SIV experiments. All authors read and approved the final manuscript.